A year has passed since the Ministry of Health, Labor and Welfare (MHLW) announced its package strategy to fuel the early commercialization of software as a medical device (SaMD) in November last year. A growing number of drug makers are…
ACADEMIA
Oita University to Begin PI Study for Replicon RNA Vaccine in October
Oita University plans to start a first-in-human PI clinical trial for its replicon RNA vaccine against COVID-19 in the middle of October. It hopes to confirm the vaccine’s safety and immunogenicity in PI, with an eye to the launch of…
To read the full story
Related Article
ACADEMIA
- Swift Actions to Improve Diagnostic System, Control Costs Required to Prep for Potential Aducanumab Debut: JSDR Confab
November 30, 2021
- Anti-CGRP Antibodies Cut Headaches in 70% of Patients, but Cost Will Be Major Obstacle: Specialist
October 21, 2021
- Japan Headache Society Clarifies Patients Suitable for CGRP Migraine Meds, No Drug Selection Criteria Given for Now
October 21, 2021
- For Hypertension, Entresto Expected as or More Effective than ARBs/ACE Inhibitors: Professor
October 21, 2021
- NCC Kicks Off Asia’s Clinical Data Sharing Project, Starting with Bowel Cancer
October 4, 2021
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…